EGFR and non-small cell lung carcinoma: It was reported that serum level of KRT19 was associated with the efficacy of EGFR-TKI treatment in NSCLC harboring EGFR mutation, and that patients with high KRT19 responded poorly to EGFR-TKI, leading to a shorter survival time 41.